
Home » Thomson Reuters launches new clinical trial intelligence solution
Thomson Reuters launches new clinical trial intelligence solution
October 18, 2013
The Intellectual Property and Science business of Thomson Reuters, a provider of intelligent information for businesses and professionals, has announced the addition of Clinical Trials Intelligence to the Thomson Reuters Cortellis suite, a comprehensive information solution for drug discovery and development.
The Thomson Reuters Life Sciences team has invested in Cortellis, creating a unique platform for drug researchers and developers to assess and integrate content from multiple sources, so they can confidently make time-sensitive, drug-related decisions. Clinical trial information is now part of the Cortellis content collection.
"Clinical research has changed dramatically during the last decade," said John Brett-Harris, managing director of Thomson Reuters Life Sciences. "Clinical trials are now driven not only by traditional clinical characteristics of disease, but by molecular profiling, signaling pathways and gene sequencing. Cortellis Clinical Trials Intelligence supports this transformation and allows customers to connect clinical trials to our other content programmatically."
Cortellis Clinical Trials Intelligence enables users to access and search information on more than 140,000 U.S. and global trials for biologics, diagnostics, biomarkers, medical devices and drugs targeting rare diseases. The solution also includes access to 200,000 press releases, 220,000 fully abstracted literature articles, 2.25 million articles related to clinical development supporting unparalleled outcome searching, 21,000 meeting abstracts, 8,000 conference reports and transcripts of biomedical and medicinal chemistry industry analyst and investor meetings. It offers full integration with Thomson Reuter’ drug pipeline and patent content and is available via the web portal or an application programming interface (API).
The solution provides visualizations that support fact-based decision making and enhance competitive positioning. It includes a trial timeline viewer that provides an up-to-date view of trial start dates, insights on trial duration trends and expected, actual or projected end dates for a given indication, company or drug. Cortellis Clinical Trials Intelligence also supports precision medicine strategies through the discovery of competitor activity for specific patient segments, biomarker utilization and novel insights into disease processes.
The solution is designed to accelerate clinical trial development, improve outcomes, decrease time to market and maximize portfolio strategies for professionals in all areas of biopharm companies including clinical development and operations, R&D, marketing, business development plus vendors supporting clinical trial planning and execution.
Upcoming Events
-
05Dec
-
14Apr